Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 1162-1165

  Kavsak, Peter A ^a   Henderson, Matthew ^a   Moretto, Patricia ^b   Hirte, Hal ^b   Evans, Ken ^c   Wong, Donald ^d   Korz, Walter ^d   Hotte, Sebastien J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c Ontario Cancer Biomarker Network   (Canada)

^d Chemokine Therapeutics Corporation   (Canada)

Author keywords

Cell adhesion; Cytokines; Metastasis; Phase I II study

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; CYTOKINE; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHIP; BREAST CANCER; CANCER CONTROL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CYTOKINES; DEMOGRAPHY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349192258     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.04.008     Document Type: Article

References (10)

1. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brunner N., Chan D.W., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for us of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 54 (2008) e11-e79
2. Wong D., and Korz W. Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin. Cancer Res. 14 (2008) 7975-7980
3. Kavsak P.A., Lee A., Hirte H., Young E., and Gauldie J. Cytokine elevations in acute coronary syndrome and ovarian cancer: a mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clin. Biochem. 41 (2008) 607-610
4. Kavsak P.A., Ko D.T., Newman A.M., Lustig V., Palomaki G.E., MacRae A.R., et al. Vascular versus myocardial dysfunction in acute coronary syndrome: are the adhesion molecules as powerful as NT-proBNP for long-term risk stratification?. Clin. Biochem. 41 (2008) 436-439
5. Kavsak P.A., Ko D.T., Newman A.M., Palomaki G.E., Lustig V., MacRae A.R., et al. Upstream markers provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. Clin. Chim. Acta 387 (2008) 133-138
6. Kavsak P.A., Ko D.T., Newman A.M., Palomaki G.E., Lustig V., MacRae A.R., et al. Risk stratification for heart failure and death in an acute coronary syndrome population using inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin. Chem. 53 (2007) 2112-2118
7. Norman G.R., and Streiner D.L. Principle components and factor analysis. Biostatistics-The Bare Essentials. 3rd ed (2008), BC Decker Inc, Hamilton 194-209
8. Ottaiano A., Franco R., Talamanca A.A., Liguori G., Tatangelo F., Delrio P., et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin. Cancer Res. 12 (2006) 2795-2803
9. Wyscozynski M., Reca R., Ratajczak J., Kucia M., Shirvaikar N., Honczarenko M., et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 105 (2005) 40-48
10. Griffioen A.W. Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol. Immunother. 57 (2008) 1553-1558